Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

MoneyShow presents top investment ideas for 2024 from leading advisors. Part 7 includes Village Super Market, MARA Holdings, ...

First Solar will report financial results for the fourth quarter and full year ended Dec. 31, 2024, after the closing bell on ...

Eli Lilly and Company (NYSE:LLY – Free Report) had its price target reduced by Wells Fargo & Company from $1,000.00 to ...

Dividend-screened portfolios of various kinds have failed to keep up with the broad US stock market over the past 10 years, ...

We recently compiled a list of the 12 Safest Stocks to Buy According to Hedge Funds. In this article, we are going to take a ...

Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

Citi lowered the firm’s price target on Merck (MRK) to $125 from $130 and keeps a Buy rating on the shares. Ahead of the Q4 earnings, the firm ...

Wells Fargo lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,000 and keeps an Overweight rating on the shares. The firm ...

Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...